the gene expression profiling, there was a 96% chance that the primary malignancy was lymphoma.
The patient's bulky pelvic adenopathy recurred less than a month after completion of cyclophosphamide, doxorubicin, vincristine, and prednisone treatment. Positron emission tomography CT scanning showed additional new lesions involving the mediastinum, midesophagus, and bones. She developed daily fevers, drenching sweats, and increasing weakness, and her weight decreased by 30 pounds. A new right inguinal lymph node biopsy in April 2012 showed similar morphologic and immunohistochemical findings as her previous biopsy, although more numerous tumor cells were seen in this subsequent biopsy. The differential diagnosis on the repeat biopsy included classical Hodgkin lymphoma (cHL), anaplastic large-cell lymphoma (ALCL), and metastatic, poorly differentiated carcinoma. Numerous atypical mitoses and apoptotic figures were seen along with necrosis. Additional immunostains showed that the tumor cells also expressed CD4, CD33, CAM5.2, and Wilms' tumor 1, but were negative for a large panel of antibodies including ALK1, paired box gene-5, and other T-cell antigens (CD1, CD2, CD3, CD5, CD7, and CD8). T-cell receptor (TCR) gamma rearrangement studies showed a biclonal TCR rearrangement (Fig 1F) . The molecular results, the morphology, and the immunophenotype were most consistent with an anaplastic lymphoma kinase(ALK) -negative ALCL with aberrant cytokeratin expression. The patient began treatment with the CD30-targeted antibody-drug conjugate brentuximab vedotin; however, she died less than 1 week after treatment initiation.
Discussion
To our knowledge, this is the first case of ALCL with this unique cytokeratin immunoprofile to be reported in the English language medical literature. Lymph node involvement by a malignancy with pleomorphic morphology can be challenging to diagnose when the cells have an overlapping immunoprofile, given that many metastases can involve nodal sites. ALCL is a type of non-Hodgkin T-cell lymphoma that can involve lymph nodes and uniformly expresses CD30. It was first recognized by Stein et al 1 in 1985, who described 45 cases with CD30 (Ki-1 antigen) expression and prominent sinusoidal invasion that had previously been diagnosed as malignant histiocytosis or anaplastic carcinoma. ALK-negative ALCL is a subtype of ALCL that is a T-or null-cell phenotype and lacks ALK1 protein expression/ALK translocation. The majority of ALCLs shows a clonal rearrangement of the TCR ␥ and ␤ chain genes, irrespective of whether or not they express T-cell antigens.
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The differential diagnosis of ALCL includes cHL, metastatic carcinoma, melanoma, peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), other malignant lymphomas, histiocytic sarcoma, and embryonal carcinoma. Evaluation of the expression of epithelial markers such as cytokeratin AE1, CAM5.2, EMA, and OSCAR is routinely used to identify poorly differentiated carcinoma. 4 Some early studies showed that some cytokeratins, such as AE1, are specific and helpful in distinguishing carcinoma from lymphoma and melanoma. 5 However, subsequent studies showed rare and limited expression of cytokeratins in B-cell lymphomas, cHL, PTCL-NOS, and even plasma-cell myeloma. 6, 7 One study of 18 cases of ALCL showed staining in 11% of cases with CK2 (an antibody specific for keratin 18) and 28% of cases with KL1 (a pan keratin). 6 In some situations, ALKnegative ALCL diagnosis can be challenging when CD45 and other T-cell antigens are not expressed and other markers, such as myeloid antigens (CD33), are present that can cause concern for a myeloid sarcoma or other malignancies. 8 One large study that analyzed 866 cases of lymphoma and leukemia showed rare expression of CK8, CK5/6, and CK22 in 1.5% of cases (n ϭ 13); these included 0.4% of cHLs (one of 230), 0.6% of diffuse large B-cell lymphomas (two of 326), and 4% of PTCL-NOS (one of 27). 7 A larger number of ALCLs show positivity for EMA, and EMA has been reported more frequently in ALK-positive than ALK-negative ALCL (83% v 43%) 9, 10 ; thus, the use of EMA alone to distinguish between ALCL and metastatic carcinoma should be avoided.
Another diagnostic difficulty is that other nonlymphoid lesions can show expression of CD30, a cell membrane protein of the tumor necrosis factor receptor family, including embryonal carcinomas, osteogenic sarcomas, mesotheliomas, seminomas, Ewing sarcoma, salivary gland carcinomas, and rare lymphoepithelial carcinomas. 11 In some situations, other ancillary studies such as electron microscopy have helped to distinguish a carcinoma from a cytokeratin-positive lymphoma by showing the characteristic electron microscopy features of epithelial differentiation, such as tonofibrils and desmosomes. 11, 12 CUP is a clinically recognized disorder that accounts for 3% to 5% of all malignant epithelial tumors. 13, 14 In the last several years, molecular assays have become important in determining the tissue of origin. These molecular assays include gene expression profiling (GEP) microarrays, microRNA quantitative reverse-transcriptase polymerase chain reaction assays, and other reverse-transcriptase polymerase chain reaction assays. 14 Tissue of origin determination is clinically important because it can allow a specific type of therapy to be given on the basis of the identification of the primary of tissue of origin, which may improve survival. However, currently, the role of molecular platform testing in clinical practice is unknown. Sites of involvement of CUP can include liver, lung, peritoneal cavity, lymph nodes, and bones. Several clinical features for CUP are characteristically seen: short history with symptoms and signs associated with the metastatic sites, early metastasis in the absence of a primary tumor, aggressive clinical course, unpredictable metastatic patterns, and a third of patients can demonstrate involvement of three or more organs at the time of diagnosis. 14 Our case was unusual and challenging, given that the expression of multiple cytokeratins (CAM5.2, EMA, OSCAR, AE1/AE3), lack of CD45, and lack of clonal T-and B-cell receptor gene rearrangement studies in the initial biopsy led to the consideration of CUP. Although GEP was performed 5 months after the initial biopsy and showed a higher probability of lymphoma, the presence of numerous admixed benign B and T cells and limited numbers of tumor cells in the initial biopsy prevented us from excluding the possibility of profiling of benign lymphocytes in the initial biopsy. Nevertheless, a repeat TCR rearrangement study on a subsequent biopsy that contained more numerous tumor cells and showed a biclonal TCR rearrangement enabled the final diagnosis of cytokeratin-positive, ALK-negative ALCL. Thus, our patient's therapy could be more specifically targeted toward a relapsed CD30 ϩ lymphoma with drugs such as brentuximab vedotin, instead of relying on empirical chemotherapeutic treatment for CUP. Preliminary data in a phase I study have shown promising results; brentuximab vedotin caused tumor regression in 86% of patients (36 of 42) with relapsed or refractory CD30 ϩ lymphomas. 15 A recent phase II clinical trial using brentuximab vedotin in 58 patients with relapsed or refractory systemic ALCL demonstrated a response in the majority of the patients: 50 patients (86%) showed an objective response, 33 patients (57%) showed complete remission, and 17 patients (29%) showed partial remission. 16 In summary, a comprehensive clinicopathologic work-up that includes repeat biopsy and molecular testing with GEP in conjunction with T-or B-cell receptor gene rearrangement studies may help to differentiate a rare cytokeratin-positive lymphoma from a metastatic carcinoma if a case with an unusual immunoprofile should be encountered in clinical practice. Our case also demonstrates the utility of continued clinical vigilance, repeat B-or T-cell receptor gene rearrangement studies, and multiple biopsies in the evaluation of these rare cytokeratin-positive lymphomas. 
